Breaking News: A Game-Changer for Diabetes Prevention in Australia?
In a move that could significantly impact the lives of millions, the Pharmaceutical Benefits Advisory Committee (PBAC) has recommended that Wegovy (semaglutide) be subsidized through the Pharmaceutical Benefits Scheme (PBS) for adults with established cardiovascular disease and obesity. But here's where it gets controversial: while this decision aims to make the medication more affordable, it raises questions about accessibility for those who could benefit most but don’t meet the strict criteria.
Diabetes Australia’s Group CEO, Justine Cain, has warmly welcomed the recommendation, along with comments from Federal Health Minister Mark Butler indicating the government’s commitment to work with manufacturer Novo Nordisk to list the medication. This collaboration is expected to lower costs, making Wegovy more accessible to Australians who need it.
And this is the part most people miss: supporting individuals in their weight loss journey is a cornerstone of type 2 diabetes prevention. Cain emphasizes, ‘Ensuring the affordability of medicines that aid in weight loss is critical, as it directly contributes to reducing the risk of type 2 diabetes.’ While genetics and family history play a role, a staggering 58% of type 2 diabetes cases can be prevented or delayed through lifestyle changes and interventions like these.
The PBAC’s published recommendation specifies that the subsidy should be provided ‘for adults with established cardiovascular disease (eCVD) and obesity, who have already experienced a cardiovascular event such as a heart attack, stroke, or symptomatic peripheral arterial disease.’ This narrow focus, while important, leaves out a significant portion of the population who could benefit from early intervention.
The Diabetes Alliance, led by Diabetes Australia, played a pivotal role in advocating for this outcome. Their joint submission to PBAC’s November 2025 meeting highlighted the importance of access to GLP-1 RA medicines like semaglutide for obesity treatment, given the heightened risk of chronic conditions such as type 2 diabetes and heart disease. Cain expressed satisfaction with the sector’s advice being positively received, stating, ‘This recommendation is a helpful step in managing obesity and reducing chronic disease rates in Australia.’
But here’s the bold question: Is limiting access to Wegovy to those with established cardiovascular disease the best approach, or should we be expanding eligibility to include at-risk individuals earlier in their health journey? With over 1.3 million Australians living with type 2 diabetes and another 2 million at risk, this decision could shape the future of preventive healthcare in the country.
What do you think? Should the criteria for accessing subsidized Wegovy be broadened, or is the current approach justified? Share your thoughts in the comments below and join the conversation!
